FRM
CAPR icon

Fox Run Management’s Capricor Therapeutics CAPR Stock Holding History

Fox Run Management’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$546K Buy
+22,666
New +$687K 0.09% 441
2025
Q2 		– Sell
-22,360
Closed -$212K – 894
2025
Q1 		$212K Buy
+22,360
New +$310K 0.03% 783

Other funds holding CAPR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Fox Run Management's CAPR Position: Q2 2026 in Review

Fox Run Management opened a new position in Capricor Therapeutics (CAPR) in Q2 2026: 22,666 shares worth $546K. The stake represents 0.09% of the portfolio and ranks #441 among its holdings. This is a return to the name: Fox Run Management previously reported a position in CAPR as recently as Q1 2025.

Fox Run Management first reported a position in CAPR in Q1 2025 and has held it in 2 quarters since. 170 funds tracked by Wall St. Rank hold CAPR as of Q2 2026.

  • Fox Run Management held 22,666 shares of Capricor Therapeutics worth $546K as of Q2 2026.
  • Capricor Therapeutics was a new Fox Run Management position in Q2 2026.
  • Capricor Therapeutics made up 0.09% of Fox Run Management's portfolio in Q2 2026, its #441 holding.
  • Fox Run Management first reported a position in Capricor Therapeutics in Q1 2025 and has held it in 2 quarters since.
  • 170 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q2 2026.

Based on Fox Run Management's 13F filing for Q2 2026, filed 4 Aug 2026.